{"id":"genetic-tailored-antithrombotic-strategy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major or minor)"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach uses genetic testing and patient-specific characteristics to guide the choice and dosing of anticoagulant or antiplatelet agents, rather than applying a one-size-fits-all treatment paradigm. By identifying genetic variants affecting drug metabolism (such as CYP2C9, VKORC1, or CYP3A4 polymorphisms) and other individual risk factors, the strategy aims to reduce thrombotic events while minimizing bleeding complications.","oneSentence":"A personalized anticoagulation strategy that tailors antithrombotic therapy selection based on individual genetic and clinical factors to optimize efficacy and safety.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:39:48.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism prevention and treatment"},{"name":"Acute coronary syndrome management"}]},"trialDetails":[{"nctId":"NCT04502017","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2020-08-05","conditions":"Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":364,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Genetic-Tailored AntiThrombotic Strategy","genericName":"Genetic-Tailored AntiThrombotic Strategy","companyName":"Texas Cardiac Arrhythmia Research Foundation","companyId":"texas-cardiac-arrhythmia-research-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A personalized anticoagulation strategy that tailors antithrombotic therapy selection based on individual genetic and clinical factors to optimize efficacy and safety. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Acute coronary syndrome management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}